ReviewBMC ophthalmology2026
Unilateral vitreous amyloidosis as the presenting feature of hereditary transthyretin amyloidosis (TTR p.Val50Met): a case report and focused literature review.
Review in BMC ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundHereditary transthyretin amyloidosis (ATTRv) is an autosomal dominant systemic disorder characterized by extracellular amyloid deposition. Ocular manifestations typically present bilaterally, and unilateral vitreous amyloidosis without systemic symptoms or family history is rare. Few reports have documented the laterality pattern of vitreous amyloidosis or its role as an early indicator of systemic disease. CASE PRESENTATION: We present a 67-year-old Chinese man who experienced progressive left eye vision loss over 1 year. Dense vitreous opacities in the left eye initially mimicked vitreous hemorrhage or primary intraocular lymphoma. The right eye showed only age-related posterior vitreous detachment and foveal drusen, without clinically apparent vitreous amyloid; its isolated intraocular pressure elevation was not accompanied by optic disc or visual field damage. After exclusion of infectious and neoplastic etiologies through aqueous humor analysis, diagnostic pars plana vitrectomy combined with phacoemulsification and intraocular lens implantation was performed under general anesthesia. Histopathological examination revealed Congo red-positive amyloid deposits with apple-green birefringence. Genetic testing identified a heterozygous pathogenic TTR variant (NM_000371.4:c.148G > A:p.V50M). Postoperatively, decimal visual acuity improved from counting fingers to 0.4 at 1 week and 0.5 + at the last follow-up. No systemic symptoms of amyloidosis were present; systemic evaluation was recommended.
conclusionsThis case demonstrates that ATTRv can present as unilateral vitreous amyloidosis. Our focused PubMed-based review suggests that although vitreous amyloidosis is typically bilateral, unilateral or markedly asymmetric presentation occurs and may be the presenting feature of disease. Late-onset V50M carriers remain at risk for polyneuropathy and cardiomyopathy. Ophthalmologists should consider TTR amyloidosis in unexplained unilateral vitreous opacities and initiate long-term multidisciplinary surveillance.
Indexed as
Identifiers
42855664What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.